Tetraspanins in Mast Cells by Martin Köberle et al.
REVIEW ARTICLE
published: 07 May 2012
doi: 10.3389/ﬁmmu.2012.00106
Tetraspanins in mast cells
Martin Köberle, Susanne Kaesler ,Wolfgang Kempf , FlorianWölbing andTilo Biedermann*
Department of Dermatology, Eberhard Karls University Tübingen, Tübingen, Germany
Edited by:
Ulrich Blank, Institut National de la
Santé et de la Recherche Médicale,
France
Reviewed by:
Marc Benhamou, Institut National de
la Santé et de la Recherche Médicale,
France
Frank A. Redegeld, Utrecht University,
Netherlands
*Correspondence:
Tilo Biedermann, Department of
Dermatology, Eberhard Karls
University, Liebermeisterstrasse 25,
72076Tübingen, Germany.
e-mail: tilo.biedermann@med.
uni-tuebingen.de
Mast cells (MC) are keymediators of the immune system,most prominently known for their
role in eliciting harmful allergic reactions. Mast cell mediator release (e.g. by degranulation)
is triggered by FcεRI recognition of antigen – IgE complexes. Until today no therapeutic
targeting of this and other mast cell activation pathways is established. Among possible
new candidates there are tetraspanins that have been described on MC already several
years ago. Tetraspanins are transmembrane proteins acting as scaffolds, mediating local
clustering of their interaction partners, and thus amplify their activities. More recently,
tetraspanins were also found to exert intrinsic receptor functions. Tetraspanins have been
found to be crucial components of fundamental biological processes like cell motility and
adhesion. In immune cells, they not only boost the effectiveness of antigen presentation
by clustering MHC molecules, they are also key players in all kinds of degranulation events
and immune receptor clustering. This review focuses on the contribution of tetraspanins
clustered with FcεRI or residing in granule membranes to classical MC functions but also
undertakes an outlook on the possible contribution of tetraspanins to newly described mast
cell functions and discusses possible targets for drug development.
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INTRODUCTION
Tetraspanins are evolutionary conserved and are expressed ubiq-
uitously (Levy and Shoham, 2005). They are composed of the
four eponymous transmembrane (TM) domains, connected by
a small and a large extracellular as well as an intracellular loop
(Figure 1). The large extracellular loop consists of two subdo-
mains, a conserved three-helix structure that contains a canonical
CCG motif and a variable region that is inserted within the con-
served subdomain and is responsible for some of the speciﬁc
protein-protein interactions of individual tetraspanins. A stretch
of residues located in the TM2 – intracellular loop – TM3 region
is also highly conserved and referred to as the tetraspanin signa-
ture. In the conserved regions, there are a number of canonical
cysteine residues that ether serve as palmitoylation sites or form
disulﬁde bonds that establish the topology of the large extracellu-
lar region (Seigneuret et al., 2001). Tetraspanins have a different
primary sequence anddonot share anyhomologieswith themulti-
gene four-transmembrane family proteins (MS4A) that comprise,
e.g., CD20 and the high-afﬁnity IgE receptor β chain (FcεRIβ),
although the secondary structure of these proteins also forms four
transmembrane domains (Ishibashi et al., 2001). Tetraspanins are
able to form homodimers and to cluster with a large number of
transmembrane proteins like integrins, major histocompatibility
complex proteins and Fc receptors, but also with intracellular sig-
naling molecules like phosphatidylinositol-4-kinase or RhoA. The
clustering of tetraspanins leads to the formation of distinct mem-
brane domains called tetraspanin enriched microdomains (TEM;
Figure 2). By spatial enrichment of their binding partners, they
bring together interacting elements of signaling pathways and also
cluster homotypic signaling, thus amplifying signaling amplitudes
(Hemler, 2005; Yanez-Mo et al., 2009).
Tetraspanin research started in the 1980s. While some were
soon established as important cell surface markers, others were
long neglected. Major problems were that no mouse antibodies
could be raised against some human tetraspanins or that no bio-
logical functions could be elucidated because initially no classical
receptor/ligand functionswere observed (Hemler, 2005;Yanez-Mo
et al., 2009).
In the last years, exciting new functions have been elucidated
for tetraspanins. Not only their role as scaffold proteins is increas-
ingly appreciated, e.g., in antigen presentation by dendritic cells
(Unternaehrer et al., 2007), but also direct action of tetraspanins as
receptors has been described lately, e.g., for IL-16 (Qi et al., 2006)
or hepatitis C virus entry (Pileri et al., 1998).
Mast cells (MC) are tissue-homing immune cells that differ-
entiate from blood borne committed progenitor cells and have
been identiﬁed in all vertebrate classes (Crivellato and Ribatti,
2010). Preferentially populating surface organ tissues such as the
skin or mucosal surfaces in the gut, MC contribute to the ﬁrst
line defense system against pathogens (Echtenacher et al., 1996).
The discovery that MC are much more than an effector cell of
type I allergic reactions challenged a paradigm, but was soon con-
ﬁrmed by other studies (for review see (Sayed et al., 2008;Abraham
and St John, 2010; Beghdadi et al., 2011). In addition, MC were
shown to be crucial mediators of delayed type hypersensitivity
reactions (DTHR) of the skin (Biedermann et al., 2000), joints
(Lee et al., 2002; Kneilling et al., 2007) and brain (Secor et al.,
2000).
While some of these MC functions were questioned recently
based on the model systems used (Zhou et al., 2007; Dudeck et al.,
2011; Feyerabend et al., 2011), the critical role of MC for cuta-
neous DTHR was conﬁrmed in different models (Biedermann
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FIGURE 1 |Tetraspanin structure scheme (modified from Levy and Shoham, 2005).
FIGURE 2 | Clustering of various tetraspanins, with integrins and Fcε
receptors, forming a tetraspanin enriched microdomain.
et al., 2000; Dudeck et al., 2011; Otsuka et al., 2011). More-
over, it was discovered that MC functions are determined by the
surrounding microenviroment of their destination and different
situations of, e.g., inﬂammationor regeneration allowMC to adapt
“as needed” (Pennock and Grencis, 2004, for review see Hallgren
and Gurish, 2007; Collington et al., 2011). Signals and pathways
involved in these adaptive processes have not been well character-
ized. In contrast, molecular pathways triggered by IgE-mediated
MC activation have been studied in detail.
In mammals,MC express tetrameric high-afﬁnity receptors for
IgE (FcεRI) as well as stem cell factor receptors (c-kit, CD117) on
the cell surface. Signaling events downstream of FcεRI are medi-
ated by a large multi-protein complex, sometimes called the FcεRI
signalosome mainly consisting of kinases and adaptor proteins
(Draber et al., 2012). Upon FcεRI crosslinking by antigen – IgE
complexes large intracellular granules are released that store a vari-
ety of mediators, among them histamine and proteases (tryptases,
chymases; Amin, 2012). Additionally, upon activation they syn-
thesize from arachidonic acid leukotrienes (e.g. leukotriene C4)
that add to the recruitment of leukocytes (Mandal et al., 2008).
These features highlight MC as key players in allergic and inﬂam-
matory reactions. In addition, subsequently to degranulation after
FcεRI crosslinking mediator release from MC is continued, con-
tributing to delayed immune responses following MC activation.
Some of the very early events following FcεRI crosslinking even
distinguish between mediator release from granules and cytokine
production including downstream immune consequences (Shu-
milina et al., 2008; Sobiesiak et al., 2009). In the last decade, MC
and MC mediators have been increasingly appreciated as instruc-
tors of other cells in immune reactions by the release of cytokines
or cell contact dependent signaling (Bradding et al., 1994; Sayed
et al., 2008). For example, MC derived TNF has been shown to be
crucial for neutrophil recruitment and local endothelial inﬂam-
mation (Biedermann et al., 2000; Kneilling et al., 2009). While
most prominently associated with allergic and autoimmune dis-
eases as well as infections, MC and MC derived mediators also
play an important role in the detoxiﬁcation of insect or snake
venoms (Metz et al., 2006; Akahoshi et al., 2011). This may be
especially interesting, as it indicates also a physiologic relevance
of venom speciﬁc IgE and IgE-dependent MC activation: low
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level sensitization and IgE-mediatedMC activationmay have con-
tributed to survival following intoxications and lead to a positive
selection of this activation pathway during evolution.
By and large, tetraspanin expression and function in MC and
basophils and in the variety of responses in which MC and
basophils contribute have not been very well characterized. How-
ever, it is clear that tetraspanins play an important role in MC
functions, because they are closely linked to FcεRI signaling and
degranulation. Furthermore, they may also play an important role
in some of the rather newly described MC functions, but this
remains to be determined.
DISTRIBUTION AND FUNCTION OF TETRASPANINS IN MC
AND BASOPHILS
CD9
On their search for an antibody speciﬁc to lymphohematopoi-
etic progenitors, Kersey et al. (1981) identiﬁed CD9 (TSPAN29,
Leukemia-Associated Cell Surface Antigen p24, Motility-Related
Protein-1) by a monoclonal antibody (mAb) that bound to acute
lymphoblastic leukemia cells.
CD9 is expressed on a wide variety of cells, including B
cells, T cells, dendritic cells, platelets, and endothelial cells. By
immunophenotyping humanMC,CD9 has been detected on sub-
types such as bone marrowMC, skinMC, renal MC, tonsillar MC,
uterine MC, cardiac MC, lung MC as well as on basophils (Guo
et al., 1992; Sperr et al., 1994; Fureder et al., 1997; Beil et al., 1998;
Escribano et al., 1998; Ghannadan et al., 1998). Malignant MC
clones express CD9 as well, though in contrast to CD63 no upreg-
ulation compared tohealthyMChasbeendescribed (Baghestanian
et al., 1996; Jost et al., 2001).
Data gained from experiments with platelets show co-
localization and most likely functional interaction of CD9 and
FcγRII, which is also the predominant FcγR in MC (Huang et al.,
1992; Moseley, 2005). Degranulation of rat basophil leukemia
(RBL) cells transfected with CD9 could be triggered by mAb
directed against CD9 but not with F(ab′)2 fragments of thesemAb.
Therefore, these data argue that the artiﬁcial mAb treatment acts
as a surrogate for IgE coated antigen leading to FcεRI clustering as
well. While co-localization of CD9 and FcεRI was also proven by
co-precipitation, no functional consequences were documented
(Higginbottom et al., 2000).
IL-16 has been described as CD4 ligand inducing T helper cell
chemotaxis and IL-2 receptor expression (Parada et al., 1998).
However, MC migrate and maturate in response to IL-16 as well
and while some MC lines and human cord blood derived MC do
express CD4, human bone marrow and peripheral MC are CD4
negative. Even in the case of CD4 expression, IL-16 dependent
migration is abrogated only partially by a CD4 blocking antibody
treatment of MC and othermonocytes (Sperr et al., 1994; Kirshen-
baum et al., 2003; Qi et al., 2006). In the quest for an additional
receptor, unexpectedly CD9was identiﬁed as a receptor conferring
IL-16 responsiveness to MC by induction of PI3K signaling and
Ca2+ inﬂux (Qi et al., 2006).
CD9, CD81 (see below), and FcεRI have been shown to be
co-expressed and co-localized in human dendritic cells. In these
cells, co-activation of FcεRI (by crosslinking) and CD9 (by mAb)
resulted in increased IL-10 production (Peng et al., 2011).
A CD9 blocking antibody exists (Chen et al., 1999), and was
shown to block MC migration in vitro (Qi et al., 2006). However,
and in contrast to some other MC tetraspanins, it is unknown
whether it affects degranulation. If so, it could be used in combi-
nation with other tetraspanin blocking antibodies and thus might
synergistically increase the effectiveness of a tetraspanin target-
ing treatment option intended to ameliorate the symptoms of
erratic MC activation in allergic disease. If it furthermore blocks
chemotaxis also in vivo, it might also prevent MC accumulation at
sites affected. CD9 has been described to expose a conformation
dependent epitope when clustered with activated β1-integrins. A
mAb directed against this epitope could mimic the PI3K activa-
tion (Gutierrez-Lopez et al., 2003). Hence it would be interesting
to know if this epitope is also involved in IL-16 induced PI3K
signaling by CD9.
CD63
CD63 (TSPAN30, Granulophysin, Melanoma Antigen ME491,
Platelet Glycoprotein 40 kDa, sometimes ambiguously lamp-3)
was the ﬁrst tetraspanin that has been cloned in 1988 from human
cancer cells (Hotta et al., 1988). Three years later it was already
demonstrated to be located in the vicinity of the FcεRI on RBL-
2H3 basophils (Kitani et al., 1991). If used in high concentrations,
the antibody directed against CD63 moderately inhibited degran-
ulation. In experiments with RBL cells transfected with human
CD63, two out of ﬁve mAb clones speciﬁc for hCD63 stimulated
degranulation in the absence of any further stimuli. The addition
of a secondary antibody did not further increase degranulation,
arguing against a mechanism of mere crosslinking (Smith et al.,
1995). The authors of these studies thus speculated that CD63
might be a mediator or promoter of FcεRI signaling, but at that
time, no experimental evidence supported this hypothesis. Instead
it had been shown intracellularly to co-localize with lamp-1 and
lamp-2 on lysosomes (Metzelaar et al., 1991) and on endosomes.
Importantly, CD63 is also present on various kinds of secretory
granules. It has been detected on basophil granules (Knol et al.,
1991), but also on platelet granules (Nishibori et al., 1993), the
granzyme/perforin containing granules of cytotoxic T cells (Peters
et al., 1991) and the von Willebrand Factor/P-selectin containing
Weibel Palade bodies of endothelial cells (Vischer and Wagner,
1993). CD63 is targeted to lysosomes byC-terminalGYEVMmotif
that is recognized by the adaptor protein AP-3 subunit μ3 (Rous
et al., 2002) and has been found to be cycling between endocytic
vesicles and secretory granules (Kobayashi et al., 2000).
In the event of granule exocytosis, CD63 containing granule
membrane fuses with the plasma membrane. Therefore, CD63
soon was used extensively as activation marker of basophils (Knol
et al., 1991) andMC (reviewed inValent et al., 2001). Close spatial
examination of the site of CD63+ vesicle exocytosis showed that
it is roughly targeted into the direction of the stimulus, but spares
the site of FcεRI crosslinking. This is in contrast to CD63− recy-
cling endosomes, which are also exocytosed in response to FcεRI
activation and are targeted directly to the site of the stimulus (Wu
et al., 2007). When additional activation markers were uncovered,
we deﬁned a group of activation markers that behaved like CD63,
consisting of CD63 and CD107a and indicating anaphylactic exo-
cytosis of large granules. The surface exposure time course of
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these “slow” activation markers parallels that of histamine release,
in contrast to the “fast” CD203c group (CD203c, CD13, CD64)
that rather indicates piecemeal degranulation (Hennersdorf et al.,
2005).
However, even under steady state conditions many types of
human MC showed constitutive CD63 surface expression. This
included skin MC, renal MC, tonsillar MC, lung MC, uterus MC,
and gastrointestinal MC as well as cultured MC progenitors from
cord blood and basophils (Fureder et al., 1997; Beil et al., 1998;
Ghannadan et al., 1998; Krauth et al., 2005; Schernthaner et al.,
2005). Furthermore, patients with indolent systemic mastocytosis
showed upregulated CD63 on MC (Escribano et al., 1998).
Interactions of various integrins and tetraspanins have been
observed in many cell types. Tetraspanins have been shown
to be important for integrin mediated intercellular adhesion,
regulate integrin mediated cell motility and are involved in
integrin signaling (Berditchevski, 2001). CD63 is no exception
from the rule that integrins are classical interaction partners of
tetraspanins. For example, CD63 has been found associated with
LFA-1 (CD11a/CD18) and some mAb against CD63 triggered
increased cell adhesiveness probably resulting fromSrc kinase acti-
vation (Skubitz et al., 1996). Recently, in a very similar ﬁnding
interaction of CD63 and β1-Integrin triggered by their natural lig-
and ameloblastin resulted in Src activation as well (Iizuka et al.,
2011). In a major advance in the quest for the role of CD63 inMC
with a blockingmAb directed against CD63 not onlyMC adhesion
to ﬁbronectin and vitronectin could be inhibited but also FcεRI
mediated degranulation of adherentMC. Furthermore, theAbwas
sufﬁcient to inhibit FcεRI mediated degranulation in rats. While
no effect on tyrosine phosphorylation was observed, the Gab2
PI3K pathway known to affect adhesion as well as degranulation
was shown to be suppressed (Kraft et al., 2005).
Work focusing on intracellular CD63 showed co-localization of
CD63 with the SNARE proteins VAMP-7 and syntaxin 3 together
with N -ethylmaleimide-sensitive factor (NSF; Puri et al., 2003).
SNARES are proteins mediating the fusion of granule membrane
with the plasma membrane and NSF is an ATPase initiating
SNARE disassembly (reviewed by Benhamou and Blank, 2010).
SNARE disassembly “primes”MC, enabling further degranulation
events. Recently, a mAb was developed that speciﬁcally recognizes
CD63 of granular origin. Speciﬁcity was found to depend on a
glucosylation pattern only present on the intracellular isoform.
Recognizing CD63 that had reached the cell membrane during a
previous degranulation event, this Ab proved thatMC can degran-
ulate at least a second time in response to a different IgE-antigen
stimulus (Schafer et al., 2010). These ﬁndings are complemented
by a report that investigated the superior stimulus provided by par-
ticulate antigens (pAg). The authors show long lasting interaction
of pAg/IgE/FcεRI in CD63+ granule compartments that did not
occur when soluble antigen was administered instead (Jin et al.,
2011).
New ﬁndings show involvement of the autophagy pathway in
degranulation and co-localization of CD63 with the autophagy
marker LCR-II (Ushio et al., 2011).
The new mAb recognizing granular CD63 will be an impor-
tant tool in MC research and might also be useful as a diagnostic
tool. The capacity of the CD63 blocking antibody to block MC
activation in vivo might make it a lead for a novel therapy target-
ingMCgranule release. However, as observedwith theHermansky
Pudlak syndrome, a rare hereditary disease shown to be the result
of CD63 expression deﬁciency (Nishibori et al., 1993) high dose
application of anti-CD63 might negatively affect blood coagula-
tion. The interesting ﬁnding that CD63 promotes FcεRI signaling
only of adherentMCprompts the questionwhether integrin bind-
ing might effect an activating conformation change in associated
CD63 as has been shown for CD9 (Gutierrez-Lopez et al., 2003),
thereby amplifying intracellular FcεRI signaling.
CD81
CD81 (TSPAN28, TAPA-1) was identiﬁed as the target of an
anti-proliferative antibody with strong cDNA homology to CD63
(Oren et al., 1990). It is very broadly expressed on hematolym-
phoid, neuroectodermal, and mesenchymal cells and has been
shown to amplify B-cell- and T-cell-receptor signaling (Levy et al.,
1998). Similarly a mAb directed against CD81 was found to
down-regulate FcεRI mediated degranulation of RBL cells (Flem-
ing et al., 1997). As was later shown in a similar manner for an
CD63 speciﬁc mAb (Kraft et al., 2005, see above), this treatment
failed to inhibit FcεRI-induced tyrosine phosphorylation. Also,
calcium mobilization or leukotriene synthesis was not affected
(Fleming et al., 1997). While no signaling pathway mediating the
anti-CD81 effect could be elucidated, effectiveness of this Ab in
curing passive cutaneous anaphylaxis in rats could be demon-
strated. CD81 has been shown to associate with VLA-4 and LFA-1
and to activate their adhesiveness in lymphocytes (Levy et al.,
1998). Furthermore it was demonstrated to regulate Rac1 acti-
vation in cell migration (Quast et al., 2011). Maybe, reduction of
allergen induced airway hyperreactivity observed in CD81 deﬁ-
cient mice (Deng et al., 2000) might in part result of a disrupted
FcεRI–CD81 interaction that probably regulates FcεRI signaling
in wildtype mice. Compared to CD9 and CD63 the knowledge
and understanding of the role of CD81 in MC is quite limited. It
would be interesting to investigate whether it promotes adhesion
and migration also in MC. The potential application of block-
ing anti-CD81 as an anti-allergic treatment however, might most
prominently inhibit B cell antibody production by inhibiting sig-
naling of theCD19CD81B-cell-receptor complex (vanZelm et al.,
2010).
CD151
Immunophenotypingwith amAb raised againstmyeloid leukemia
cells identiﬁed CD151 (TSPAN24, gp27, PETA-3, Raph blood
group) on platelets and megakaryocytes as well as on various
types of myeloid, endothelial and epithelial cells (Ashman et al.,
1991; Sincock et al., 1997). The examination of CD151 on MC
was not as comprehensive as with other tetraspanins, however
it has been found on human foreskin, gastrointestinal, uterine,
lung, and cord blood derived MC as well as on basophils (Ghan-
nadan et al., 1998; Wimazal et al., 1999; Krauth et al., 2005;
Schernthaner et al., 2005). It is well established that CD151 is
co-expressed and co-localized with laminin binding integrins,
facilitating adhesion, and motility processes, the latter possibly by
mediating TEM endocytosis and recycling (Liu et al., 2007). How-
ever, there are no functional data regarding the role of CD151
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Table 1 | General molecular and prominent functional properties of tetraspanins also expressed in MC.
Name:CD,HGNC;
OMIM No.
Gene: accession,
location
Protein: accession,
size
Function (in human or murine cells)
CD9, TSPAN29;
*143030
Human: *928, 12p13.3
Mouse: *125276 F3
Human: NP_001760, 228 aa,
25.4 kDa
Mouse: NP_031683, 226 aa,
25.3 kDa
Fusion of gametes (Kaji et al., 2000), myoblasts (Tachibana and
Hemler, 1999), and virus infected cells (Lofﬂer et al., 1997);
represses tumor cell motility (Miyake et al., 1991; Ikeyama et al.,
1993); prevents monocyte fusion (Takeda et al., 2003); formation
of paranodal nerve junctions (Ishibashi et al., 2004); MHC II
multimerization (Unternaehrer et al., 2007). In MC: IL-16 receptor
in MC and other cells (Qi et al., 2006); might promote FcεRI (Peng
et al., 2011) and FcγR signaling (Huang et al., 1992).
CD63, TSPAN30;
*155740
Human: *967,
12q12-q13
Mouse: *1251210 D3
HumanA: NP_001771, 238
aa, 25.6 kDa; Human B:
NP_001035123, 236 aa,
25.4 kDa
Mouse: NP_031679, 238 aa,
25.8 kDa
Promotes tumor cell motility and migration (Radford et al., 1997);
regulates endosomal sorting (van Niel et al., 2011); cofactor for
leukocyte recruitment by endothelial P-selectin (Doyle et al., 2011);
internalization of H,K-ATPase beta-subunit in gastric parietal cells
(Dufﬁeld et al., 2003); neutrophil activation and adhesion (Skubitz
et al., 1996). Promotes MC adhesion and degranulation (Kraft
et al., 2005).
CD81, TSPAN28;
*186845
Human: *975, 11p15.5
Mouse: *125207 F5
Human: NP_004347, 236 aa,
25.8 kDa
Mouse: NP_598416, 236 aa,
25.8 kDa
Promotes CD19 expression/antibody production (van Zelm et al.,
2010); T-cell adhesion and co-stimulation (Todd et al., 1996; Sagi
et al., 2012); cell migration (Quast et al., 2011); virus entry (Pileri
et al., 1998); Plasmodium infection (Silvie et al., 2003); prevents
monocyte fusion (Takeda et al., 2003); Promotes FcεRI dependent
degranulation (Fleming et al., 1997).
CD151, TSPAN24;
*602243
Human: *977, 11p15.5
Mouse: *124767 F5
Human: NP_004348,
NP_620599$, 253 aa,
28.3 kDa
Mouse: NP_001104520, 253
aa, 28.3 kDa
Regulates integrin trafﬁc and promotes cell migration (Liu et al.,
2007); enables platelet aggregation by integrin outside-in signaling
(Lau et al., 2004); strengthens adhesion to laminin-1 (Lammerding
et al., 2003); inhibits T-cell proliferation (Wright et al., 2004);
strengthens podocyte binding to glomerular basement membrane
(Sachs et al., 2012).
Accession numbers of the respective NCBI databases (OMIM, Gene, or Protein reference sequence) are given. $Results of a transcript that lacks an alternate segment
in the 5′ UTR.
in MC yet. The data from other cell types, however, suggest
it to be an integral TEM component. Thus it is unlikely, that
CD151 present on MC is devoid of functions regarding inter-
cellular binding, migration, and recycling of TEM membrane
patches.
CONCLUDING REMARKS
Tetraspanins are closely linked to MC biology. While CD63 is
commonly used as an activation marker for human cells and co-
localization of tetraspanins with FcεRI has been known for a long
time, it has been much more difﬁcult to gain functional insights.
While knowledge about the modes of MC tetraspanin action is
increasing recently, there are very few results generated with pri-
mary cells and little attention has been paid to the fact that the
tetraspanins expressed in MC might be redundant in function.
Anyway, it is becoming increasingly clear that tetraspanins form
functional clusters with Fcε receptors and integrins on MC sur-
faces and connect them with downstream signaling components
like Src or Gab2.
The development of novel mAb that speciﬁcally recognize
CD63 of intracellular origin (Schafer et al., 2010) or that are able
to attenuateMCdegranulation by targeting CD63 or CD81 (Flem-
ing et al., 1997; Kraft et al., 2005) might improve diagnostics
and provide the basis to develop powerful tools for the treat-
ment of acute allergic reactions. Furthermore, tetraspanins might
play a key role in emerging topics of MC research: (1) MC are
regarded as important sources of TNF under pro-inﬂammatory
conditions (Biedermann et al., 2000; Kneilling et al., 2009) and
tetraspaninsmight contribute tometallo-protease cleavage of pro-
TNF as has been described for other cells (Arduise et al., 2008). (2)
Tetraspanins might be involved in establishing mast cell adhesion
and cell–cell contacts to a much larger extent than anticipated
today (Kraft et al., 2005). (3) MC are increasingly perceived as
antigen presenting cells (Kambayashi et al., 2009; Stelekati et al.,
2009), thus it is of interest if the effects of tetraspanins on anti-
gen presentation reported from dendritic cells and B cells might
also be observed in MC. (4) Recent research demonstrated MC as
a source of exosomes (Skokos et al., 2002) of which tetraspanins
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are major membrane components. As has been described for exo-
somes of many other cells types,MC exosomes stained positive for
CD63 (Valadi et al., 2007). Thus, adding to tetraspanin research
on MC plasma membrane or MC granules, MC exosomes open
an additional new ﬁeld for the examination of MC tetraspanins.
All together, accumulating evidence suggests that tetraspanins
are hitherto underrated contributors in the regulation of effec-
tor functions also in MC. Although we are still missing some
important data on tetraspanin functions in MC, already our
present understanding highlights that tetraspanins may be rel-
evant druggable targets in future therapeutic strategies to treat
allergic and possibly also other MC-dependent diseases.
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